



Exciting expansion as SpeedX adds concise gastroenteritis panels to their Research offerings.
Enteric**Plex*** products *Sharpen Your Focus*

SYDNEY, AUSTRALIA – (December 8, 2023). Innovative molecular diagnostic developer, SpeedX Pty. Ltd., have expanded their breadth of Research Use Only (RUO) products, now applying their innovative qPCR/NAAT techniques to a suite of gastroenteritis panels.

SpeedX have released three Enteric**Plex** RUO assays, each with up to 5 targets in a single-well multiplexed qPCR/NAAT assay—differing from much more extensive and expensive low-throughput panels. *“This is key for laboratories – enabling them to streamline workflows, and efficiently process high sample numbers in a cost-effective way. A win, win for them.”* – Warwick Need, SpeedX Director of Sales.

The range of concise enteric panels: Enteric**Plex** Parasite*, Enteric**Plex** Bacteria I*, and Enteric**Plex** Bacteria II* detect a range of common bacterial and parasite targets, allowing for researchers to test only for relevant targets.

*“Within the assay development process, our team conducted extensive market research – identifying key targets of concern. Laboratories can now ‘Sharpen Their Focus’ with the Enteric**Plex** assays that consist of carefully selected targets — allowing for efficient and cost-effective investigation of these organisms.”* – Colin Denver, CEO SpeedX.

Why research gastroenteritis? Gastroenteritis conditions are estimated to cause 179 million illnesses in the United States, annually¹, with acute diarrhea being one of the most reported illnesses, second only to respiratory infections². Worldwide, it is a leading cause of mortality in children younger than four years old, especially in the developing world³. Diarrhoea is defined as the abrupt onset and passage of three or more loose or liquid stools per day and is considered acute when symptoms persist beyond fourteen days.

About SpeedX Pty Ltd

Founded in 2009, SpeedX is a global company with offices in Austin, London and Sydney, and distributors across Europe. SpeedX specializes in molecular diagnostic solutions that go beyond simple detection to also offer comprehensive information on antibiotic resistance. Innovative real-time polymerase chain reaction (qPCR/NAAT) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeedX please see: <https://plexpcr.com>

*Research Use Only, not for use in diagnostic procedures

1. A. Schmidt MA, Groom HC, Rawlings AM, Mattison CP, Salas SB, Burke RM, Hallowell BD, Calderwood LE, Donald J, Balachandran N, Hall AJ. Incidence, Etiology, and Healthcare Utilization for Acute Gastroenteritis in the Community, United States. *Emerg Infect Dis.* 2022 Nov;28(11):2234-2242. doi: 10.3201/eid2811.220247. PMID: 36285882; PMCID: PMC9622243.

2. Blanca Ochoa, MD and Christina M. Surawicz, MD, MACG, University of Washington School of Medicine, Seattle, WA – Published October 2002. Updated April 2007. Updated December 2012. (<https://gi.org/topics/diarrhea-acute-and-chronic/>)

3. WHO fact sheets: Diarrhoeal disease (<https://www.who.int/en/news-room/fact-sheets/detail/diarrhoeal-disease>).

Contact:

Michelle Howie
Associate Director | Global Strategic Marketing
michelleh@speedx.com.au
+61 499 743 199